|
[Related PubMed/MEDLINE]
Total Number of Papers: 74
|
|
|
|
|
[Display Entries]
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: sIL-6R |
| Long Form |
: soluble IL-6R |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2020 |
Antinociceptive effects of IL-6R vs. glucocorticoid receptors during rat hind paw inflammatory pain. |
GR, IL-6R |
| 2 |
2020 |
Soluble IL-6R promotes chondrogenic differentiation of mesenchymal stem cells to enhance the repair of articular cartilage defects using a rat model for rheumatoid arthritis. |
AIA, HLA, MSCs, PLGA, RA, SO |
| 3 |
2019 |
Activation of Toll-like Receptor 2 (TLR2) induces Interleukin-6 trans-signaling. |
ERK, IL-6, PBMCs, TLR2 |
| 4 |
2019 |
Molecular characterization of grass carp interleukin-6 receptor and the agonistic activity of its soluble form in head kidney leucocytes. |
gcIl-6r, HKLs, IL, rgcIl-6, rgcsIl-6r, SOCS3 |
| 5 |
2018 |
Differential profiling of lacrimal cytokines in patients suffering from thyroid-associated orbitopathy. |
CAS, TAO |
| 6 |
2018 |
Dissecting Interleukin-6 Classic- and Trans-Signaling in Inflammation and Cancer. |
--- |
| 7 |
2018 |
IL-6 trans-signalling mediates trabecular, but not cortical, bone loss after ovariectomy. |
cis, IL-6, IL-6R |
| 8 |
2018 |
Interleukin-6 trans-signaling contributes to chronic hypoxia-induced pulmonary hypertension. |
CH, IL-6, mIL-6R, PASMCs, PH |
| 9 |
2018 |
The balance of interleukin (IL)-6, IL-6soluble IL-6 receptor (sIL-6R), and IL-6sIL-6Rsgp130 complexes allows simultaneous classic and trans-signaling. |
gp130, IL, IL-6R, sgp130 |
| 10 |
2018 |
The classic signalling and trans-signalling of interleukin-6 are both injurious in podocyte under high glucose exposure. |
DKD, HG, IL-6, mIL-6R, sgp130 |
| 11 |
2018 |
The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab. |
DAS, EULAR, RA |
| 12 |
2017 |
IL-6 signaling in diabetic nephropathy: From pathophysiology to therapeutic perspectives. |
CKD, DN, IL-6 |
| 13 |
2017 |
IL-6 trans-signaling is another pathway to upregulate Osteopontin. |
ADAM17, IL, OPN, PMA |
| 14 |
2017 |
The Soluble Interleukin 6 Receptor: Advanced Therapeutic Options in Inflammation. |
IL |
| 15 |
2016 |
Cleavage Site Localization Differentially Controls Interleukin-6 Receptor Proteolysis by ADAM10 and ADAM17. |
ADAM10, IL-6R |
| 16 |
2016 |
IL-6 Trans-Signaling Drives Murine Crescentic GN. |
IL-6R |
| 17 |
2016 |
Interleukin-6 receptor alpha blockade improves skin lesions in a murine model of systemic lupus erythematosus. |
ANA, IL, IL-6Ralpha, SLE |
| 18 |
2016 |
Soluble IL-6 Receptor and IL-27 Subunit p28 Protein Complex Mediate the Antiviral Response through the Type III IFN Pathway. |
--- |
| 19 |
2015 |
Contribution of the Interleukin-6/STAT-3 Signaling Pathway to Chondrogenic Differentiation of Human Mesenchymal Stem Cells. |
IL-6, IL-6R, MSCs |
| 20 |
2015 |
Secreted Frizzled-related protein 3 (sFRP3)-mediated suppression of interleukin-6 receptor release by A disintegrin and metalloprotease 17 (ADAM17) is abrogated in the osteoarthritis-associated rare double variant of sFRP3. |
ADAM17, IL-6R, sFRP3 |
| 21 |
2014 |
The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases. |
ADAM, CRP, IL-6R, SNP |
| 22 |
2013 |
Alterations of IL-6, IL-6R and gp130 in early and late onset severe preeclampsia. |
GP, IL-6, IL-6R, PE, sgp130 |
| 23 |
2013 |
An interleukin-6 receptor-dependent molecular switch mediates signal transduction of the IL-27 cytokine subunit p28 (IL-30) via a gp130 protein receptor homodimer. |
IL-6R |
| 24 |
2013 |
Enhancement of gingival inflammation induced by synergism of IL-1beta and IL-6. |
HGFs, IL-1 |
| 25 |
2013 |
Functional IL6R 358Ala allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory diseases. |
AAA, AF, CHD, IL-6, PBMCs, RA, T1D |
| 26 |
2013 |
Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjects. |
Cmax, CRP, i.v, IL-6R, PD, PK, s.c |
| 27 |
2013 |
The regenerative activity of interleukin-6. |
IL-6, IL-6R |
| 28 |
2012 |
Anti-inflammatory effect of IL-6 receptor blockade in corneal alkali burn. |
PBS |
| 29 |
2012 |
Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells. |
CSCs, IL-6R, mAb, MTX, NSCLC, siRNA |
| 30 |
2012 |
Hitting a complex target: an update on interleukin-6 trans-signalling. |
IL-6, IL-6R |
| 31 |
2012 |
Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis. |
IL-6, IL-6R, Mtb, sgp130, TB, TNF |
| 32 |
2011 |
Association of plasma IL-6 and soluble IL-6 receptor levels with the Asp358Ala polymorphism of the IL-6 receptor gene in schizophrenic patients. |
IL-6, IL-6R |
| 33 |
2011 |
Early hepatocyte DNA synthetic response posthepatectomy is modulated by IL-6 trans-signaling and PI3K/AKT activation. |
HGF, IL-6, PH |
| 34 |
2011 |
IL-6 trans-signaling system in intra-amniotic inflammation, preterm birth, and preterm premature rupture of the membranes. |
AF, IAI, IL-6R, PPROM, sgp130 |
| 35 |
2011 |
Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation. |
IL, MSLN, NF-kappaB, PC, siRNA |
| 36 |
2011 |
Role of the IL-6 classic- and trans-signaling pathways in corneal sterile inflammation and wound healing. |
MCP-1, mIL-6R, STAT3, VEGF |
| 37 |
2011 |
Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model. |
CLP, gp130, IL, IL-6R, sgp130 |
| 38 |
2010 |
Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule. |
HUVEC, PBMC |
| 39 |
2010 |
Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration. |
IL-6, IL-6R |
| 40 |
2010 |
Increased interleukin-6 activity associated with painful chemotherapy-induced peripheral neuropathy in women after breast cancer treatment. |
IL |
| 41 |
2010 |
Regulation of adenosine system at the onset of peritonitis. |
ADA, AK, sgp130-Fc |
| 42 |
2010 |
Role of IL-6 trans-signaling in CClâ‚„induced liver damage. |
IL-6 |
| 43 |
2010 |
The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells. |
CM, PCa |
| 44 |
2009 |
The effect of interleukin-6 and the interleukin-6 receptor on glucose transport in mouse skeletal muscle. |
AMPK, IL-6 |
| 45 |
2008 |
Altered interleukin-6 receptor, IL-6R and gp130, production and expression and decreased SOCS-3 expression in placentas from women with pre-eclampsia. |
IL-6, IL-6R, PE, sgp130, SOCS-3 |
| 46 |
2008 |
Cutting edge: soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells. |
--- |
| 47 |
2008 |
IL-6 transsignalling modulates the early effector phase of EAE and targets the blood-brain barrier. |
EAE, IL-6, IL-6R, MBP |
| 48 |
2008 |
Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. |
CRP, IL-6, IL-6Rs, RA |
| 49 |
2008 |
Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritis. |
CIA, IL-6R, PIP |
| 50 |
2007 |
Cytokines are a therapeutic target for the prevention of inflammation-induced cancers. |
IL-6, IL-6R |
| 51 |
2006 |
Interleukin-6 and its receptor: from bench to bedside. |
IL-6, IL-6R |
| 52 |
2006 |
Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas. |
IL-6, IL-6R, MM, MRA, STAT3, VEGF |
| 53 |
2006 |
Sleep enhances IL-6 trans-signaling in humans. |
DS, IL-6, mIL-6R, PC |
| 54 |
2005 |
Interleukin-6/soluble interleukin-6 receptor complex reduces infarct size via inhibiting myocardial apoptosis. |
IL-6, IL-6R |
| 55 |
2005 |
Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. |
CNTF, IL-11, IL-6R, LIF, mIL-6R, OSM |
| 56 |
2004 |
Novel therapy for Crohn's disease targeting IL-6 signalling. |
CD, mAb |
| 57 |
2003 |
Polymorphisms of the gene encoding the inflammatory cytokine interleukin-6 determine the magnitude of the increase in soluble interleukin-6 receptor levels in Alzheimer's disease. Results of a pilot study. |
AD, IL-6, IL-6prom, IL-6vntr |
| 58 |
2002 |
Characterization of anti-mouse interleukin-6 receptor antibody. |
IL-6R |
| 59 |
2002 |
Proteolysis of interleukin-6 receptor (IL-6R) by Porphyromonas gingivalis cysteine proteinases (gingipains) inhibits interleukin-6-mediated cell activation. |
IL-6, IL-6R |
| 60 |
2002 |
Secretion of oncostatin M by infiltrating neutrophils: regulation of IL-6 and chemokine expression in human mesothelial cells. |
OSM |
| 61 |
2001 |
Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpesvirus. |
GP, hIL-6, IL-6R, mAbs, sgp130, vIL-6 |
| 62 |
2001 |
Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. |
IL-6, LIF, OSM, sgp130 |
| 63 |
2000 |
Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. |
CD, IL, IL-6R |
| 64 |
2000 |
Human myeloma cells promote the recruitment of osteoblast precursors: mediation by interleukin-6 and soluble interleukin-6 receptor. |
IL-6R |
| 65 |
1999 |
Interleukin-6 receptor signaling. I. gp80 and gp130 receptor interaction in the absence of interleukin-6. |
IL-6 |
| 66 |
1999 |
Role of interleukin-6 and soluble IL-6 receptor in region-specific induction of astrocytic differentiation and neurotrophin expression. |
CNS, H-IL-6, IL-6, IL-6R, NGF, NTs |
| 67 |
1999 |
[Cord blood transplantation and ex vivo expansion of hematopoietic stem cells]. |
AGM, dpc, IL-6R |
| 68 |
1998 |
Combination of interleukin-6 and soluble interleukin-6 receptors induces differentiation and activation of JAK-STAT and MAP kinase pathways in MG-63 human osteoblastic cells. |
IL-6, IL-6Rs, MAP |
| 69 |
1997 |
I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. |
--- |
| 70 |
1997 |
Oncostatin M stimulates the expression and release of the IL-6 receptor in human hepatoma HepG2 cells. |
--- |
| 71 |
1997 |
Soluble IL-6 receptor leads to a paracrine modulation of the IL-6-induced hepatic acute phase response in double transgenic mice. |
--- |
| 72 |
1996 |
Accelerated Nerve Regeneration in Mice by upregulated expression of interleukin (IL) 6 and IL-6 receptor after trauma. |
IL, IL-6 |
| 73 |
1995 |
Detection of membrane and soluble interleukin-6 receptor in lymphoid malignancies. |
CLL, IL-6R, MG, NHL |
| 74 |
1992 |
Association of recombinant soluble IL-6-signal transducer, gp130, with a complex of IL 6 and soluble IL-6 receptor, and establishment of an ELISA for soluble gp130. |
ELISA, sgp130 |
|
A Search Service for Abbreviation / Long Form
